Quick Answer
LENZ Therapeutics, Inc. reported Diluted EPS of $2.85 per share (loss) for fiscal year 2025.
LENZ Therapeutics, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$2.85 | -21.8% |
| 2024 | -$2.34 | +93.4% |
| 2023 | -$35.71 | -1840.8% |
| 2022 | -$1.84 | +24.9% |
| 2021 | -$2.45 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.59 | -55.3% | -11.3% |
| June 30, 2025 | -$0.53 | -32.5% | +0.0% |
| March 31, 2025 | -$0.53 | +85.0% | -39.5% |
| September 30, 2024 | -$0.38 | +96.0% | +5.0% |
| June 30, 2024 | -$0.40 | +94.7% | +88.7% |
| March 31, 2024 | -$3.53 | +45.7% | +63.3% |
| September 30, 2023 | -$9.62 | -2037.8% | -27.8% |
| June 30, 2023 | -$7.53 | -1468.8% | -15.8% |
- LENZ Therapeutics, Inc. showed a decrease of -21.8% in Diluted EPS compared to the prior fiscal year.
- Over the 2021–2025 period, LENZ Therapeutics, Inc.’s diluted eps has declined by 16.3% (from $2.45 per share (loss) to $2.85 per share (loss)).
- The most recent figure is from LENZ Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 24, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: